Dallas, TX: ReportsandReports announce it will carry Genzyme Corporation: PharmaVitae Profile Market Research Report in its Store. Browse complete Genzyme Corporation: PharmaVitae Profile Report Introduction This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase Table of Content ABOUT DATAMONITOR HEALTHCARE 2 About the PharmaVitae team 2 Chapter 1 About this profile 3 PharmaVitae Explorer database 3 Chapter structure 3 Executive summary 3 Quarterly news update 3 Company introduction 3 Company sales 4 Company financials 4 Key products and competitors 4 Data sourcing 4 Sales data 4 Analyst consensus 4 Chapter 2 Executive summary 5 Key findings 5 Prescription pharmaceutical sales and growth rate performance, 2002-14 6 Financial performance, 2002-14 8 Genzyme: PharmaVitae forecasts at a glance 9 Strategic insight 10 Genzyme success in ultra-niche markets 10 Combination of fast revenue growth and margin improvement leads to explosive profit growth With the blockbuster model under threat, Genzyme’s niche market strategy looks set to hold firm 11 High-risk blockbuster model out-dated? 11 Genzyme’s niche market-targeting an alternative strategy 11 Greater economies of scale as rare genetic disorders franchise expands 12 Allston facility contamination impact Genzyme’s 2009 performance 12 Genzyme’s spread-risk strategy 13 The renal franchise is Genzyme’s first major example of therapeutic diversification 13 Further therapeutic diversification, emerging player in oncology 14 Acquisition of Bayer products adds further strength to oncology offering 14 SWOT analysis 18 Strengths 18 Weaknesses 19 Opportunities 19 Threats 20 Table of Contents 21 Table of figures 23 Chapter 3 Quarterly news update 24 Product developments 24 Deals and alliances 25 Product deals 25 Technology deals 26 M&A activity 27 Company announcements 28 Future product milestones 29 Chapter 4 Company introduction 30 Key findings 30 Background 31 Key corporate developments 32 M&A history 33 Bone Care International 33 AnorMED acquisition 34 Mozobil: the catalyst 34 Bioenvision 35 Current corporate structure 35 Biotherapeutics 35 LSDs 36 The rarity of LSDs offers a significant niche opportunity 36 Genetics/diagnostics 37 Chapter 5 Company sales 38 Key findings 38 Prescription pharmaceutical sales and growth rate analysis, 2002-14 39 Product analysis 42 Product analysis, 2002-08 44 Product analysis, 2008-14 47 Therapy area analysis 51 Geographic analysis 55 Launch/core/expiry analysis 58 Explanation of launch/core/expiry analysis 58 Launch analysis, 2008-14 59 Core analysis, 2008-14 60 Expiry analysis, 2008-14 61 Launch/core/expiry configuration, 2008-14 62 Molecule type analysis 64 Externalization analysis 68 Chapter 6 Company financials 71 Key findings 71 Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 72 Operating costs and profit analysis 74 Operating costs and profit analysis, 2002-08 75 Operating cost ratio and profit margin analysis, 2002-08 76 Operating cost ratio and profit margin analysis, 2008-14 77 Operating costs and profit analysis, 2008-14 78 Chapter 7 Key products and competitors 80 Key findings 80 Overview 81 Endocrine, metabolic and genetic disorders 82 Cerezyme 82 Overview 83 Sales forecast 84 A rare disorder, but significant sales growth 84 Allston manufacturing facility contamination impacts 2009 sales 84 Threat from Shire and Protalix toward the end of the forecast period 85 Long term threat from pharmacological chaperones, Shire/Amicus’s Plicera 86 Myozyme/Lumizyme 87 Overview 87 Sales forecast 88 Genzyme’s key growth driver 88 Development of Lumizyme expected to provide boost to sales 89 Fabrazyme 90 Overview 90 Sales forecast 91 Comprehensive exclusivity 91 Shire suffers blow with Replagal 91 Amicus could provide competition in the long term 92 Genitourinary 93 Renagel/Renvela 93 Overview 94 Sales forecast 95 Therapeutic diversification through M&A 95 Established product 95 Strong sales force and good safety… 95 …backed by the NKF 95 Competition does exist 96 Renvela developed in order to consolidate Genzyme’s position as number one 96 Label expansion into CKD patients not on dialysis 96 Hectorol 97 Overview 97 Sales forecast 98 Product gained through acquisition 98 Used as a complimentary product 98 Competition from Amgen 98 Oncology 99 Mozobil 99 Overview 99 Sales forecast 100 Innovative therapy supporting Genzyme’s exploration into oncology 100 Strong clinical trial data 100 Clolar 102 Overview 102 Sales forecast 103 Acquisition of Bioenvision provided Clolar and boosted Genzyme’s oncology offering 103 While approval in AML will significantly broaden Clolar’s label, increased economic constraints on healthcare systems may restrict its uptake 103 Price and further competition will impede growth 103 Central nervous system 105 Campath 105 Overview 105 Sales forecast 106 Phase II data show superior efficacy compared to Rebif 106 Safety concerns 107 Future market potential 107 Chapter 8 Appendix 109 R&D pipeline 109 References 110 Datamonitor reports 110 Abbreviations 110 About Datamonitor 112 About Datamonitor Healthcare 112 Datamonitor consulting 112 Disclaimer 114 Browse complete Genzyme Corporation: PharmaVitae Profile Report Browse all Healthcare Market Research Reports Browse all Datamonitor Market Research Reports RSS Browse all Latest Report Related Reports: Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile Genzyme Corporation Market Share Analysis Genzyme Corporation-Detailed Product Pipeline About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Posted by
Unknown
on
